Serious adverse events rare after COVID-19 boosters in young kids--studies

Serious adverse events rare after COVID-19 boosters in young kids A related study in South Korea shows waning vaccine effectiveness in teens. CIDRAP

Data collected from two vaccine safety surveillance programs in the first 10 weeks of administration of third doses of the Pfizer/BioNTech COVID-19 to US children aged 5 to 11 years show that serious adverse events were rare.

A related study in South Korea shows waning vaccine effectiveness (VE) in adolescents after two and three Pfizer doses but sufficient protection against critical illness. ...